British Columbia Biosimilar Policy Shows No Impact on Healthcare Utilization for Inflammatory Arthritis Patients
核心洞察
A population-based study of 3,004 inflammatory arthritis (搜索) patients in British Columbia (搜索) found no significant differences in healthcare utilization between those prescribed etanercept biosimilars versus originators following a 2017 policy mandate.
The policy requiring new etanercept prescriptions to use biosimilars increased biosimilar uptake from 0.06% to 78.3% without affecting hospitalization rates, emergency visits, or physician encounters over three years.
Using regression discontinuity design as a natural experiment, researchers demonstrated equivalent real-world effectiveness and safety of biosimilars compared to originator biologics in routine clinical practice.
A comprehensive population-based study examining the real-world impact of British Columbia (搜索)'s biosimilar policy has found no significant differences in healthcare utilization between patients prescribed etanercept biosimilars versus originator biologics for inflammatory arthritis (搜索) treatment.
The research, published in The Lancet Regional Health - Americas, analyzed data from 3,004 incident etanercept users between 2014 and 2020, providing crucial evidence about biosimilar performance in routine clinical practice. The study leveraged British Columbia (搜索)'s July 18, 2017 policy implementation as a natural experiment, which mandated that all new etanercept prescriptions use biosimilar versions to qualify for PharmaCare (搜索) coverage.
Policy Implementation Creates Natural Experiment
The biosimilar mandate dramatically increased uptake from just 0.06% (9 out of 1,626 patients) in the pre-policy period to 78.3% (1,079 out of 1,378 patients) in the post-policy period. This sharp transition created an ideal setting for researchers to assess real-world biosimilar effectiveness using regression discontinuity design, which mimics randomized controlled trial conditions by comparing patients who initiated treatment immediately before and after the policy change.
"Lack of confidence in biosimilars' effectiveness, safety and interchangeability has been identified as one of the top barriers impairing the adoption of biosimilar therapies," the researchers noted. "Our findings on no unintended consequences of policy change at the health system level inform decisions in biosimilar policy development and implementation in other jurisdictions."
Healthcare Utilization Outcomes Remain Stable
The study tracked five key healthcare utilization outcomes over three years: physician visits, all-cause hospitalizations, infection-related hospitalizations, length of hospital stays, and emergency room visits. Intention-to-treat analysis showed no significant impact of the biosimilar policy on any outcome measure.
For all-cause hospitalizations, the adjusted rate ratio was 0.84 (95% CI: 0.49-1.44), indicating no meaningful difference between pre- and post-policy periods. Similarly, emergency room visits showed an adjusted rate ratio of 0.91 (95% CI: 0.44-1.88), and physician visits demonstrated a rate ratio of 0.96 (95% CI: 0.82-1.12).
Infection-related hospitalizations, while rare, showed no significant changes with an adjusted rate ratio of 0.91 (95% CI: 0.21-3.86). The researchers noted that wide confidence intervals for this outcome reflected the rarity of infection-related events and suggested future studies with larger sample sizes might improve precision.
Complier Analysis Confirms Biosimilar Effectiveness
Beyond policy impact assessment, the researchers conducted complier average causal effect (CACE) analysis to evaluate actual biosimilar use among policy compliers. This analysis specifically examined patients induced to use biosimilars due to the policy change, providing direct evidence of biosimilar effectiveness in real-world settings.
The CACE analysis yielded similar results, with adjusted rate ratios showing no significant differences: 1.01 (95% CI: 0.53-1.92) for all-cause hospitalizations, 0.94 (95% CI: 0.47-1.88) for emergency room visits, and 0.84 (95% CI: 0.66-1.06) for physician visits.
Robust Methodology Addresses Previous Study Limitations
The study addressed key limitations of previous biosimilar research by focusing on incident rather than prevalent users, avoiding potential selection bias from patients with longer treatment histories. The regression discontinuity design also controlled for both observed and unobserved confounding factors that could influence treatment outcomes.
"The RD design estimates treatment effects in a non-experimental setting where treatment is determined by whether an observed continuous 'assignment' variable exceeds a known cut-off point, creating a locally randomized experiment near this threshold," the researchers explained.
Multiple sensitivity analyses confirmed the robustness of findings across different statistical approaches and bandwidth selections. A control analysis using adalimumab initiators, who were unaffected by the etanercept policy, showed no concurrent changes in healthcare utilization, supporting the specificity of the results.
Clinical and Policy Implications
The study population included patients with rheumatoid arthritis (搜索), psoriatic arthritis (搜索), and ankylosing spondylitis (搜索), with demographics showing 63.7% female participants and a mean age at diagnosis of 52.5 years. The three-year follow-up period provided substantial data on healthcare utilization patterns, with researchers tracking outcomes until etanercept discontinuation, switching to other biologics, death, or study completion.
Dr. Diane Lacaille, a co-author and holder of the Mary Pack Chair in Rheumatology Research, emphasized the clinical significance: "The equivalent real-world effectiveness and safety of etanercept biosimilars shown in this study will increase healthcare providers' and patients' confidence in prescribing and taking this important medication."
Economic Impact and Future Directions
British Columbia (搜索)'s biosimilar initiative has already generated $732 million in savings over its first five years, demonstrating the economic benefits of biosimilar adoption. The policy's success has influenced similar implementations across nearly every other Canadian province.
The researchers acknowledged study limitations, including the inability to capture direct measures of disease activity and outcomes related to non-provincially funded healthcare services. They also noted that the local nature of the regression discontinuity design means results are most applicable to patients with characteristics similar to those initiating treatment around the policy implementation date.
Future research directions include extended follow-up periods to assess long-term outcomes such as joint replacement surgery, and investigation of potential differential effects across diverse population subgroups. The study's methodology provides a framework for evaluating biosimilar policies in other jurisdictions considering similar mandates.